Literature DB >> 8625447

Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history.

M Murata1, M Tagawa, M Kimura, H Kimura, S Watanabe, H Saisho.   

Abstract

The p53 tumor suppressor gene is often mutated in various human cancers and a common polymorphism is known at codon 72 of exon 4, with two alleles encoding either arginine (CGC) or proline (CCC). Association of this polymorphism with any human cancer susceptibility has yet to be clarified. We have conducted a case-control study in Japan on the distribution of the three genotypes with 191 lung cancer patients, 152 control patients with non-cancerous pulmonary diseases and 115 colorectal cancer patients. The genotypes were examined by PCR using DNA samples from peripheral blood lymphocytes. Frequency distributions of the three genotypes were quite comparable with each other among groups, with allelic frequencies of approximately 60% for arginine and 40% for proline. The genotypic frequencies in lung cancer patients, however, were largely different between smokers and non-smokers (chi 2 = 13.5, df = 2, P < 0.001). Compared with the control and colorectal cancer patients a significant difference in genotypic frequency was observed only in non-smoker lung cancers (chi 2 = 10.9, df = 2, P < 0.01), with an excess of Arg/Arg homozygotes and a deficit of Arg/Pro heterozygotes. Our present data suggest that the p53 polymorphism affects the risk of lung cancer unrelated to smoking.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625447     DOI: 10.1093/carcin/17.2.261

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  22 in total

1.  DNA sequence variants of p53: cancer and aging.

Authors:  Y Sun; C Keshava; D S Sharp; A Weston; E C McCanlies
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

3.  p53 Arg72Pro polymorphism and risk of basal cell carcinoma: a meta analysis.

Authors:  Yanli Tian; Li Li; Rongya Yang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

5.  Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.

Authors:  Ankita Kumari; Charu Bahl; Navneet Singh; Digambar Behera; Siddharth Sharma
Journal:  Mol Biol Rep       Date:  2016-09-10       Impact factor: 2.316

Review 6.  Development and progression of colorectal neoplasia.

Authors:  Upender Manne; Chandrakumar Shanmugam; Venkat R Katkoori; Harvey L Bumpers; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

7.  Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.

Authors:  Hui Wan Chua; Daniel Ng; Serena Choo; San San Lum; Huihua Li; Li Ying Soh; Kanaga Sabapathy; Adeline Seow
Journal:  BMC Cancer       Date:  2010-03-10       Impact factor: 4.430

8.  P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects.

Authors:  Chao Zhou; Hao Chen; An Wang
Journal:  Tumour Biol       Date:  2013-05-30

9.  A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism.

Authors:  Zun-Wu Zhang; Paul Newcomb; Andrew Hollowood; Jyoti Gupta; Roger Feakins; Alan Storey; Michael J G Farthing; Derek Alderson; Jeff Holly
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

10.  P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies.

Authors:  Shengming Dai; Chen Mao; Lijun Jiang; Guisheng Wang; Hongge Cheng
Journal:  Hum Genet       Date:  2009-04-09       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.